Kiadis Pharma presents at the BIO 2008 conference in San Diego, USA
Biopharmaceutical company Kiadis Pharma announced today that the company’s Chief Executive Officer, Dr. Manja Bouman, will present at the BIO 2008 conference in San Diego, CA, USA on June 17th at 2.45 PM.
About Kiadis Pharma
Kiadis Pharma is a biopharmaceutical company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients and address high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit www.kiadis.com.
For more information please contact:
Kiadis Pharma B.V.
Eefje Simpelaar
Director Communications
Email: e.simpelaar@kiadis.com
Tel: +31 20 8884815
Mob +31 610829344
More news
- Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 8-7-2010
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ 29-11-2009
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma receives two orphan drug designations for Reviroc™ from the FDA 8-12-2008
- Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™ 4-12-2008
- Kiadis Pharma announces continued collaboration with Professor Velardi on its lead product ATIR™ 28-11-2008
